A comparative study of dirithromycin and erythromycin in bacterial pneumonia
| Autor: | K. Liippo, J. Rodrig, H. Puolijoki, O.-J. Brückner, E. Tala, J.P.H. Smits |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Adolescent Dirithromycin Erythromycin law.invention Double-Blind Method Randomized controlled trial law Internal medicine Pneumonia Mycoplasma parasitic diseases Humans Medicine Aged Antibacterial agent business.industry Respiratory disease Bacterial pneumonia Bacterial Infections Pneumonia Chlamydia Infections Middle Aged medicine.disease Anti-Bacterial Agents Surgery Community-Acquired Infections Clinical trial Infectious Diseases Female Macrolides Legionnaires' Disease business medicine.drug |
| Zdroj: | Journal of Infection. 28:131-139 |
| ISSN: | 0163-4453 |
| Popis: | Dirithromycin, a new once-daily macrolide, was studied in a multicentre, randomised, double-blind trial in community-acquired bacterial pneumonia. A total of 591 patients received either a single daily dose of dirithromycin, 500 mg, or erythromycin, 250 mg, four times daily. Clinical response rates were similar in both treatment groups (127 dirithromycin-treated and 118 erythromycin-treated patients): at the time of the final consultation, the clinical and bacteriological response rates for dirithromycin-treated patients were 94.5% and 93.0%, while for erythromycin-treated patients, they were 92.1% and 90.3%, respectively. The nature and frequency of treatment-emergent events were comparable. We conclude that dirithromycin, 500 mg, once daily, is safe and effective in the treatment of community-acquired bacterial pneumonia. The once daily dose is likely to improve compliance, making it preferable to erythromycin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|